Successful sperm extraction and live birth after radiation, androgen deprivation and surgical castration for treatment of metastatic prostate cancer
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
ANDROLOGIA, v.49, n.1, article ID e12578, 5p, 2017
Resumo
Fertility preservation has become an important aspect of cancer treatment given the gonadotoxic effects of oncologic therapies. It is now considered standard of care to offer sperm banking to men undergoing treatment for primaries that affect young individuals. Less is known regarding fertility preservation of patients afflicted with prostate cancer. This cohort has progressively expanded and grown younger in the post-PSA era. Prostatectomy, radiation, chemotherapy and androgen blockade all pose unique challenges to the infertility specialist. Optimum management becomes even more uncertain for those men with metastatic prostate cancer. Most of these individuals will have received multiple forms of therapy, each carrying a distinct insult to the patient's reproductive potential. We describe a case of successful ex vivo sperm extraction and live birth in a patient previously treated with radiation and chronic androgen deprivation for metastatic prostate cancer. The presented case demonstrates that conception after radiation therapy and chronic androgen deprivation is feasible. We propose that fertility counselling and sperm cryopreservation should be considered for all prostate cancer patients. Additionally, for those individuals undergoing external beam radiotherapy, testicular shielding should be routinely offered in the event further family building is desired.
Palavras-chave
Fertility preservation, IVF-ICSI, metastatic prostate cancer, radiotherapy, sperm extraction
Referências
- Boehmer D, 2005, STRAHLENTHER ONKOL, V181, P179, DOI 10.1007/s00066-005-1282-1
- Carmignani L, 2007, HUM REPROD, V22, P1068, DOI 10.1093/humrep/del468
- Daniell HW, 2001, CANCER, V91, P1889, DOI 10.1002/1097-0142(20010515)91:10<1889::AID-CNCR1211>3.0.CO;2-U
- de Souza GL, 2011, BJU INT, V108, P1860, DOI 10.1111/j.1464-410X.2011.10131.x
- Descombe L, 2008, FERTIL STERIL, V90, DOI 10.1016/j.fertnstert.2007.07.1308
- Grocela J, 2005, BJU INT, V96, P781, DOI 10.1111/j.1464-410X.2005.05764.x
- Group ECW, 2001, HUM REPROD, V16, P1518
- Haddad N, 2014, FERTIL STERIL, V101, P956, DOI 10.1016/j.fertnstert.2013.12.052
- Hotaling JM, 2013, FERTIL STERIL, V99, P464, DOI 10.1016/j.fertnstert.2012.09.031
- Hourvitz A, 2008, FERTIL STERIL, V90, P557, DOI 10.1016/j.fertnstert.2007.03.002
- Hussein S, 2015, J CLIN PATHOL, V68, P511, DOI 10.1136/jclinpath-2015-202993
- Knoester PA, 2007, UROLOGY, V69, P123, DOI 10.1016/j.urology.2006.09.036
- Lee SJ, 2006, J CLIN ONCOL, V24, P2917, DOI 10.1200/JCO.2006.06.5888
- MANN DR, 1985, FERTIL STERIL, V43, P115
- ROWLEY MJ, 1974, RADIAT RES, V59, P665, DOI 10.2307/3574084
- Salonia A, 2013, FERTIL STERIL, V100, P367, DOI 10.1016/j.fertnstert.2013.03.049
- Shupnik MA, 1997, J ANDROL, V18, P341
- Smithwick EB, 2001, TISSUE CELL, V33, P262, DOI 10.1054/tice.2000.0164
- Steinsvik EA, 2008, BJU INT, V102, P793, DOI 10.1111/j.1464-410X.2008.07739.x
- Tournaye H, 2014, LANCET, V384, P1295, DOI 10.1016/S0140-6736(14)60495-5
- WEINBAUER GF, 1987, J ANDROL, V8, P319
- Williams DH, 2009, J UROLOGY, V181, P736, DOI 10.1016/j.juro.2008.10.023